Matthias Tschöp

Matthias Tschöp
Born April 7, 1967 (age 50)
Munich, Germany
Nationality German
Institutions Helmholtz Pioneer Campus, Helmholtz Diabetes Center, and Institute for Diabetes and Obesity at Helmholtz Zentrum München; Technische Universität München
Education Ludwig-Maximilians-Universität München
Known for Novel drug candidates for diabetes and obesity based on gut-brain signals
Notable awards Erwin Schrödinger Preis (2014); Paul Martini Prize (2014); Outstanding Scientific Achievement Award, American Diabetes Association (2011); Scientific Achievement Award, The Obesity Society (2007)

Matthias H. Tschöp (born April 7, 1967) is a German physician and scientist best known for novel therapeutic approaches to diabetes and obesity based on dissecting gut-brain communication. He is Alexander-von-Humboldt Professor[1] and Chair of Metabolic Diseases at Technische Universität München. In addition, he serves as Director of Biomedicine at Helmholtz Pioneer Campus, Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity at Helmholtz Zentrum München.[2] Matthias Tschöp also holds an Adjunct Professorship at Yale University and was elected into the German National Academy of Sciences Leopoldina in 2013.[3]

Career and research

Matthias Tschöp obtained an M.D. from the Ludwig Maximilian University of Munich (1993) where he worked as a clinician (1994-1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999-2002) and leading a research team at the German Institute of Human Nutrition (Potsdam/Nuthetal 2002-2003). He served as a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003-2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009-2011).[4]

Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in Nature is among today’s most frequently cited metabolism research papers.[5] It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.

Together with his close collaborator Richard DiMarchi (Indiana University)[6] he discovered and validated novel gut hormone co-agonist peptides, which simultaneously target several neuroendocrine receptors and efficiently reduce body weight and improve glucose tolerance. Several of these compounds are now in clinical trials for the treatment of diabetes and obesity. Tschöp and DiMarchi more recently went on to discover and validate another class of drug candidates by engineering peptide to deliver steroid/small molecules to selected cell populations.[7]

Awards and recognition

References

  1. ↑ Award winners 2012: Prof. Dr. Matthias Tschöp. humboldt-professur.de. Retrieved on 2014-01-15.
  2. ↑ St. Fleur, Nicholas (August 22, 2016). "Seeing Through to a Mouse’s Nervous System". Retrieved August 24, 2016.
  3. ↑ Professor Dr. Matthias Tschöp elected member of the German National Academy of Sciences. Eurekalert.org. Retrieved on 2015-01-22.
  4. ↑ American Society for Clinical Investigation (ASCI). the-asci.org. Retrieved on 2015-01-22.
  5. ↑ Tschöp M, Smiley D, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000;407(6806):908-13. PMC 11057670.
  6. ↑ Claiborn, Kathryn (August 1, 2011). Masters of Metabolism: Matthias Tschöp and Richard DiMarchi. jci.org. Retrieved on 2015-01-22.
  7. ↑ Gruber, Karl (March 2015). Moving toward a more precise treatment of diabetes. thelancet.com. Retrieved on 2015-02-21.
  8. ↑ Erwin Schrödinger Preis goes to Helmholtz Zentrum München. helmholtz-muenchen.de. Retrieved on 2015-01-15.
  9. ↑ Moore, Charles (December 10, 2014). ‘Unparalleled’ Results In Animal Trials Treatment To Cure Adult-onset Diabetes, Obesity. diabetesnewsjournal.com. Retrieved on 2015-02-15.
  10. ↑ Paul Martini Prize: Award for new approaches in the treatment of diabetes and obesity. paul-martini-stiftung.de. Retrieved on 2015-01-14.
  11. ↑ Gill Center for Biomolcular Science. indiana.edu. Retrieved on 2015-01-14.
  12. ↑ Prof. Dr. Matthias Tschöp. leopoldina.org. Retrieved on 2015-01-14.

Prof. Matthias Tschöp (2012-05-16). Medicine: Prof. Matthias Tschöp. Alexander von Humboldt Foundation. 

Prof. Matthias Tschöp, Chair of Metabolic Diseases, TUM School of Medicine

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.